Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
- EligibilityCriteria: Inclusion Criteria:  confirmed intrahepatic cholangiocarcinoma with Resectable tumor lesion no contraindications to surgery with high risk of tumour recurrence No prior systemic therapy for intrahepatic cholangiocarcinoma. ECOG Performance Status of 0 or 1 Child-Pugh Class: Grade A  Exclusion Criteria:  History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment Known genetic or acquired hemorrhage or thrombotic tendency Thrombosis or thromboembolic event within 6 months prior to the start of study treatment Cardiac clinical symptom or disease that is not well controlled Hypertension that can not be well controlled through antihypertensive drugs - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult